Core Insights - QIAGEN has launched QIAsymphony Connect, an advanced automated nucleic acid purification platform, at the AMP 2025 meeting, aimed at enhancing liquid biopsy applications [1][2][3] Product Innovations - QIAsymphony Connect builds on over 3,000 placements of its predecessor and is designed for improved speed, sample traceability, and digital connectivity [2][5] - The platform features superior extraction performance, higher throughput (up to 50% more samples), optimized workflows for high-sensitivity oncology applications, full sample traceability, and seamless connectivity with laboratory information management systems (LIMS) [6][5] Strategic Partnerships - QIAGEN is showcasing its partnerships in precision oncology, including a collaboration with Myriad Genetics to develop a homologous recombination deficiency (HRD) assay for cancer profiling [3][5][12] - The QIAseq xHYB HRD Panel can be combined with the QIAseq xHYB CGP Panel for comprehensive genomic profiling, analyzing 724 cancer-relevant genes and key therapy biomarkers [9][12] Market Positioning - The introduction of QIAsymphony Connect reflects QIAGEN's commitment to advancing sample technologies and supporting laboratories in processing complex samples with greater precision and speed [4][5] - QIAGEN's presence at AMP 2025 emphasizes its leadership in providing Sample to Insight solutions for both research and clinical applications [3][4]